Zucara Therapeutics

A @TIAPToronto & @adMare_Bio portfolio company developing the first once-daily therapeutic to prevent #hypoglycemia in people with #diabetes. #T1D

[Zucara Therapeutics @Zucara_ca]

Continuing our focus in Type 2 diabetes, this daily dosing study helps us to understand ZT-01’s effects with prolonged exposure as we develop a long-acting version. #lowbloodsugar #T1D #T2D #ZucaraTherapeutics

https://t.co/LzfqyqCOUs

[Zucara Therapeutics @Zucara_ca]

Thrilled to announce the final closing of Zucara’s US$25M Series B financing supported by Sanofi, the Perceptive Xontogeny Venture Fund and the T1D Fund, one of the largest disease-focused investing funds in the world.
https://t.co/3EDcA8C4ed

[Zucara Therapeutics @Zucara_ca]

Zucara is honoured to be named by @LifeSciencesON as Emerging Company of the Year. We are so grateful for the support of so many as we develop ZT-01, a first-in-class therapeutic to help people manage their diabetes.
https://t.co/kNZtbARFOm

[Zucara Therapeutics @Zucara_ca]

Honoured to be included among these amazing entrepreneurs. Excited for 2025!

#healthcare #innovation #entrepreneurship #startup #marsdd #diabetes

https://t.co/pGvK5AxO6E

[Zucara Therapeutics @Zucara_ca]

With great excitement, Zucara announces our US$20M Series B financing supported by new strategic investor, Sanofi and existing investor, the Perceptive Xontogeny Venture Fund
https://t.co/pimCRrf2k1

[T1D Exchange @T1DExchange]

Research study for people living with #T1D! See if you may be eligible for a #clinicaltrial to see if an investigational drug reduces the risk of low glucose levels at night.

https://t.co/hYg18AOarh

[Zucara Therapeutics @Zucara_ca]

Zucara’s CSO, Richard Liggins, has been invited to present on a panel at #EASD2024 organized by The Helmsley Charitable Trust .

https://t.co/hodgCTZ4p2

#Hypoglycemia #Type1Diabetes #Type2Diabetes #T1D #T2D #AlphaCells #BetaCells #Glucagon

[Zucara Therapeutics @Zucara_ca]

Great week at the ADA Diabetes conference in Orlando with 4 poster presentations and lots of good interactions and meetings.

[Zucara Therapeutics @Zucara_ca]

@MCRiddell1 @enhance_d @SamNathanScott @FedeYFontana That's really cool. The colours are very helpful on the map to show where the low happened.

[Helmsley Charitable Trust @HelmsleyTrust]

We’re excited to share that in September, we’ll host a one-day meeting on the occasion of EASD2024 featuring leaders in the field exploring key questions in hypoglycemia research. Abstracts submissions are invited to be considered for a poster session and short talks.

People with type 1 diabetes (#T1D) have an impaired response to hypoglycemia, or low blood sugar, which can lead to potentially dangerous complications. The underlying mechanisms remain poorly understood, and more research is needed in this area — better treatments could transform daily life for millions of people with T1D around the world.

Helmsley is committed to supporting research into this area. That’s why we’re convening researchers to stimulate discussion and advance the field. Learn more about this exciting event on our website: https://t.co/txbU2fqrPN

[EASD @EASDnews]

A recent study by Gilberte Martine-Edith and co-authors has highlighted that #hypoglycaemia during sleep may have been underestimated and present suggestions for future studies. See more on https://t.co/aDVo7gpJ33

#hypoglycaemia, #T1D, #diabetes, #HypoResolve

[Zucara Therapeutics @Zucara_ca]

Zucara is excited to present at the 2024 Bloom Burton & Co. Healthcare Investor Conference this week. We will provide an update on Zucara’s progress with ZT-01 and our current Phase 2 “ZONE” clinical study to prevent nighttime hypoglycemia. #BBHIC2024

[Zucara Therapeutics @Zucara_ca]

Here is a nice article about Zucara’s Phase 2 “ZONE” clinical study. Find out more about this trial and how ZT-01 is being developed to prevent nighttime hypoglycemia.

https://t.co/MyYvoVPISV

[Zucara Therapeutics @Zucara_ca]

Celebrating these amazing and bright women on the Zucara team! Happy International Women's Day. #InternationalWomensDay2024

[Zucara Therapeutics @Zucara_ca]

Zucara presented its positive proof-of-concept Phase 1b results in two presentations at the #EASD2023 Diabetes conference this week receiving high interest.

[Zucara Therapeutics @Zucara_ca]

Big milestone for Zucara as we dosed our first patient in the Phase 2a ZONE study! The ZONE study will evaluate the effect of ZT-01 on preventing nighttime hypoglycemia (low blood glucose) in people with Type 1 diabetes.
https://t.co/qC4fb2GLA0

[Zucara Therapeutics @Zucara_ca]

Richard Liggins, Zucara's CSO, in action presenting at the Boulder Peptide Symposium this week. Lots of questions and interest in the talk.

[Zucara Therapeutics @Zucara_ca]

We look forward to presenting our Phase 1b proof-of-concept data for ZT-01 at this weekend’s ADA diabetes conference in a session focused on new treatments for people with diabetes.
#diabetes #ada2023 #T1D

[Zucara Therapeutics @Zucara_ca]

We are so grateful for JDRF’s ongoing support and this US$2M of funding for our Phase 2 trial aimed to show prevention of hypoglycemia in people with T1D.
https://t.co/tFMnIkxZP6

[Michael Riddell, PhD @MCRiddell1]

Riddell preclinical lab @YorkUniversity. What a great team of students pulling together over the last ~5 very busy experimental weeks…and then sharing cooking expertise together today